OTCMKTS:AFFY - Affymax Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0390 0.00 (0.00 %)
(As of 08/19/2018 09:41 AM ET)
Previous Close$0.0390
Today's Range$0.0390 - $0.0405
52-Week Range$0.0110 - $0.0570
Volume2,025 shs
Average Volume16,434 shs
Market Capitalization$880,000.00
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Affymax logoAffymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Receive AFFY News and Ratings via Email

Sign-up to receive the latest news and ratings for AFFY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:AFFY
CUSIP00826A10
Phone650-812-8700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares37,490,000
Market Cap$880,000.00

Affymax (OTCMKTS:AFFY) Frequently Asked Questions

What is Affymax's stock symbol?

Affymax trades on the OTCMKTS under the ticker symbol "AFFY."

Who are some of Affymax's key competitors?

Who are Affymax's key executives?

Affymax's management team includes the folowing people:
  • Mr. Mark G. Thompson, CFO & Sec. (Age 56)
  • Mr. Jonathan M. Couchman, CEO, Pres & Director (Age 48)
  • Dr. Tracy J. Dunn Ph.D., J.D., VP of Intellectual Property & Legal Affairs (Age 55)

Has Affymax been receiving favorable news coverage?

News articles about AFFY stock have trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Affymax earned a media and rumor sentiment score of 0.16 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.12 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Affymax.

How do I buy shares of Affymax?

Shares of AFFY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affymax's stock price today?

One share of AFFY stock can currently be purchased for approximately $0.0390.

How big of a company is Affymax?

Affymax has a market capitalization of $880,000.00.

How can I contact Affymax?

Affymax's mailing address is 19200 STEVENS CREEK BOULEVARD SUITE 240, CUPERTINO CA, 95014. The biopharmaceutical company can be reached via phone at 650-812-8700 or via email at [email protected]


MarketBeat Community Rating for Affymax (OTCMKTS AFFY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Affymax and other stocks. Vote "Outperform" if you believe AFFY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFFY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.